Osteonecrosis Treatment Market Key Players Analysis Bone Therapeutics, Enzo Biochem Inc., and K-Stemcell Co Ltd. Hospitals, clinics, universities

Advanced Therapy Medicinal Products (ATMPs) to boost osteonecrosis treatment market. Advanced Therapy Medicinal Products is a class of innovative therapies that comprises of gene therapy, somatic cell therapy, and tissue-engineered products, which is expected to drive growth of osteonecrosis treatment market. Osteonecrosis usually affects young population and this significantly will contributes towards growth of osteonecrosis treatment market.

For instance, according to the American College of Rheumatology, in 2017, around 10,000 to 20,000 people in the U.S. who suffered from osteonecrosis were between the ages of 20 and 50. Currently, the osteonecrosis non-surgical treatment (medication) is symptomatic treatment that targets the symptoms and try to cure the disease. Hence, emerging players in the field of bone disease treatment is gaining momentum by introducing gene regulation approach.

Download PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1490

Key players like Enzo Biochem, Inc. and Bone Therapeutics are aiming gene regulation and cell-based product treatment, which is expected to augment growth of osteonecrosis treatment market. For instance, PREOB manufactured by Bone Therapeutics, a cell based medicinal product derived from autologous bone marrow stem cells has been approved in the U.S., however, it is currently in phase III in Europe.

In spite of being a rare disease, osteonecrosis treatment market is expected to propel due to the prevalence of causative agent for osteonecrosis. Side effects of various medicines taken during cancer, HIV/AIDS, osteoarthritis, osteoporosis or blood disorders or medical treatment such as chemotherapy, radiation therapy, high-dosage of steroids or organ transplants may increases the chances of having osteonecrosis.

Furthermore, few interventions such as Stanford University’s sponsored project aims at evaluation of osteonecrosis before and after decompression surgery with ferumoxytol-enhanced MRI, which improve detection and allow to track transplanted bone marrow cells. This intervention is in phase 4 clinical trial and is expected to complete the project over the forecast period, which in turn will propel growth of the osteonecrosis treatment market.

For instance, according to NCBI 2015, it is estimated that around 20,000 to 30,000 new patients are diagnosed with osteonecrosis annually in the U.S. Asia Pacific is also expected to witness faster growth in the global osteonecrosis treatment market over the forecast period, owing to increase in development activities by various key players in this region. For instance, Bone Therapeutics and Asahi Kasei Corporation signed a license agreement in 2017 for the development and commercialization of PREOB in Japan.

Major players involved in osteonecrosis treatment market include Bone Therapeutics, Enzo Biochem Inc., and K-Stemcell Co Ltd. Hospitals, clinics, universities, and institutes are other major participants in the osteonecrosis treatment market.

Get Request Sample Copy of Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1490

Osteonecrosis Treatment Market Taxonomy

By Drug Class

Non-steroidal anti-inflammatory drugs (NSAIDS)
Anti-coagulant
Other drugs
By Distribution Channels

Hospitals pharmacies
Retail pharmacies
Online pharmacies

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.